Skip to search formSkip to main contentSkip to account menu

selexipag

Known as: 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (3)

ACT 293987NS-304Uptravi

Broader (3)

AcetamidesAntihypertensive AgentsPyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Guidelines for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension characterized by a progressive obliterative… 
2020
2020
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
2019
2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD‐PAH) after defect correction have a… 
Review
2017
Review
2017
Selexipag for the treatment of pulmonary arterial hypertension.
PURPOSE The pharmacology, pharmacokinetics, clinical efficacy, safety and tolerability, dosing and administration, and place in… 
Review
2017
Review
2017
Selexipag: A Review in Pulmonary Arterial Hypertension
Selexipag (Uptravi®) is an orally active, first-in-class, selective prostacyclin IP receptor agonist. Selexipag was approved… 
Review
2015
Review
2015
The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.
Highly Cited
2015
Highly Cited
2015
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor. Decreased prostacyclin production… 
Highly Cited
2015
Highly Cited
2015
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
PurposeTargeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients… 
Highly Cited
2014
Highly Cited
2014
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy…
Objective: The objective of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of… 
2010
2010
JPET # 169748 2 RUNNING TITLE PAGE Running Title : Selexipag and gastric function Corresponding
word count: 250 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)